Beta Blockers and Melanoma

  • Aleksandra Vojvodic Department of Dermatology and Venereology, Military Medical Academy, Belgrade, Serbia
  • Petar Vojvodic Clinic for Psychiatric Disorders “Dr. Laza Lazarevic”, Belgrade, Serbia
  • Tatjana Vlaskovic-Jovicevic Clinic for Psychiatric Disorders “Dr. Laza Lazarevic”, Belgrade, Serbia
  • Goran Sijan Clinic for Plastic Surgery and Burns, Military Medical Academy, Belgrade, Serbia
  • Sanja Dimitrijevic Department of Gynecology, Military Medical Academy, Belgrade, Serbia
  • Zorica Peric-Hajzler Military Medical Academy, Belgrade, Serbia
  • Dusica Matovic Military Medical Academy, Belgrade, Serbia
  • Wollina Uwe Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Dresden, Germany
  • Michael Tirant University Guglielmo Marconi, Rome, Italy
  • Van Thuong Nguyen National Hospital of Dermatology and Venereology, Hanoi, Vietnam
  • Massimo Fioranelli Department of Nuclear Physics, sub-nuclear and radiation, G. Marconi University, Rome, Italy
  • Torello Lotti University of Rome G. Marconi, Rome, Italia
Keywords: beta blockers, melanoma

Abstract

Understanding the mechanisms of cancer immune-tolerance is one of the most important challenges. Several studies have demonstrated the potential anticarcinogenic effects of beta-blockers, in patients with prostate cancer, breast cancer, and melanoma. At the other side variety of dermatoses may be caused or aggravated by β-blockers-psoriasis, lichen planus-like drug eruptions (LDE), acrocyanosis, alopecia etc.   Beta-blockers have been shown to improve the prognosis of melanoma patients significantly. Propranolol inhibits melanoma by downregulating the tumour angiogenesis but also tumour cell proliferation, invasiveness and local immune suppression. Studies showed that only β3-but, not β2-adrenoceptors, were up-regulated under hypoxia in peripheral blood mononuclear cells and selectively expressed in immune cell sub-populations including Treg, MDSC, and NK. They increased NK and CD8 number and cytotoxicity. Catecholamines may retard melanoma progression and that β-blockers may have unrecognised potential as a therapeutic intervention for melanoma, in the prevention of the growth of melanoma in all stages and as adjuvant therapy with other targeted and immune therapies for melanoma.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

Author Biography

Torello Lotti, University of Rome G. Marconi, Rome, Italia

Prof. Lotti is Full Professor of the Dermatology and Venereology at University of Studies Guglielmo Marconi, Rome, Italy. He is Honorary Professor of Dermatology - China Medical University Shenyang (2011), Lecturer at the New York Academy of Sciences "Howard Fox Memorial Lecture" (14 March 2012 - New York, NY – USA), and Chair, Executive Scientific Committee Vitiligo Research Foundation, New York , NY , USA. He is President of the World Health Academy, Dermatology since 2013. He has been Full Professor of the Dermatology and Venereology Division at University of Florence School of Medicine, Florence, Italy, from 2006 to 2010. He is Visiting Professor in six International Universities worldwide, and Key Note Lecturer in several international dermatology Societies. His activities in serving Dermatology have been numerous: President of the Italian Society of Dermatology and Venereology (SIDeMaST , 2009-2010) and President of the International Society of Dermatology ( ISD, 2009-2010), President of the European Society for Cosmetic and Aesthetic Dermatology (2003-2004), Editor in Chief of the Journal of the European Academy of Dermatology and Venereology (1992-2002) , Editor "Therapeutic Hotline"- Dermatologic Therapy (2007-)and served as Editor in Chief of the Giornale Italiano di Dermatologia in the period of presidency of the Societa' Italiana di Dermatologia (2009-2010). He has been President of numerous international congresses and is currently Editor in Chief of the Giornale Italiano di Dermatologia e Venereologia ( 2010-2020 ). He is Ordinary Member of the main Scientific Societies worldwide (EADV, SIDEV , ESDR , ISD, AAD, SID) and Honorary Member of several Scientific Societies of the Dermatology field. Moreover, he is a Scientific reviewer of ten sectorial journals, among which are the British Journal of Dermatology, Journal of Investigative Dermatology, Journal of the American Academy of Dermatology , Dermatologic Therapy. He has authored 1054 scientific publications (393 peer reviewed articles, 288 books chapters e 365 abstracts). For more information, see www.torellolotti.it

References

De Giorgi V, et al. Epidemiology of melanoma: is it still epidemic? What is the role of the sun, sunbeds, Vit D, betablocks, and others? Dermatol Ther. 2012; 25(5):392-6. https://doi.org/10.1111/j.1529-8019.2012.01483.x PMid:23046017

De Giorgi V, Grazzini M, Gandini S, Benemei S, Lotti T, Marchionni N, Geppetti P. Treatment with β-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med. 2011; 171(8):779-81. https://doi.org/10.1001/archinternmed.2011.131 PMid:21518948

De Giorgi V, et al. Epidemiology of melanoma: is it still epidemic? What is the role of the sun, sunbeds, Vit D, betablocks, and others? Dermatol Ther. 2012; 25(5):392-6. https://doi.org/10.1111/j.1529-8019.2012.01483.x PMid:23046017

Calvani M, et al. β3-Adrenoreceptors Control Mitochondrial Dormancy in Melanoma and Embryonic Stem Cells. Oxid Med Cell Longev. 2018. https://doi.org/10.1155/2018/6816508 PMid:30538804 PMCid:PMC6258109

Tatu AL, Elisei AM, Chioncel V, Miulescu M, Nwabudike LC. Immunologic adverse reactions of β-blockers and the skin. Exp Ther Med. 2019; 18(2):955-959. https://doi.org/10.3892/etm.2019.7504 PMid:31384329 PMCid:PMC6639944

Kao J, Luu B. Can propranolol prevent progression of melanoma? JAAPA. 2019; 32(6):1-5. https://doi.org/10.1097/01.JAA.0000558241.84003.91 PMid:31136408

Dal Monte M, Calvani M, Cammalleri M, Favre C, Filippi L, Bagnoli P.

β-Adrenoceptors as drug targets in melanoma: novel preclinical evidence for a role of β3-adrenoceptors. Br J Pharmacol. 2019; 176(14):2496-2508. https://doi.org/10.1111/bph.14552 PMid:30471093

Sang Y, Deng Y. Current insights into the epigenetic mechanisms of skin cancer. Dermatol Ther. 2019; 32(4):e12964. https://doi.org/10.1111/dth.12964 PMid:31081988

Mervis JS, McGee JS. Epigenetic therapy and dermatologic disease: moving beyond CTCL. J Dermatolog Treat. 2019; 30(1):68-73. https://doi.org/10.1080/09546634.2018.1473550 PMid:29726727

Published
2019-08-30
How to Cite
1.
Vojvodic A, Vojvodic P, Vlaskovic-Jovicevic T, Sijan G, Dimitrijevic S, Peric-Hajzler Z, Matovic D, Uwe W, Tirant M, Nguyen VT, Fioranelli M, Lotti T. Beta Blockers and Melanoma. Open Access Maced J Med Sci [Internet]. 2019Aug.30 [cited 2020Oct.26];7(18):3110-2. Available from: https://www.id-press.eu/mjms/article/view/oamjms.2019.782

Most read articles by the same author(s)

1 2 3 > >>